RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Public ClinicalTrials.gov record NCT04105270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)
Study identification
- NCT ID
- NCT04105270
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- Oral Restorative Microbiota Therapy (RMT) Capsules Drug
- Durvalumab 1500 mg IV Drug
- Cisplatin/pemetrexed or Carboplatin/pemetrexed Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2022
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
- Last update posted
- Sep 10, 2025
2022 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 2
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Amit Kulkarni | Phoenix | Arizona | 85338 | Not yet recruiting |
| MNCCTN Essentia Health St. Joseph's Brainerd Medical Center | Brainerd | Minnesota | 56401 | Recruiting |
| MNCCTN Essentia Health Deer River | Deer River | Minnesota | 56636 | Recruiting |
| MNCCTN Essentia Health St. Mary's Detroit Lakes Clinic | Detroit Lakes | Minnesota | 56501 | Recruiting |
| MNCCTN Essentia Health Duluth | Duluth | Minnesota | 55805 | Recruiting |
| MNCCTN Essentia Health Fosston | Fosston | Minnesota | 56542 | Recruiting |
| MNCCTN Essentia Health Hibbing Clinic | Hibbing | Minnesota | 55746 | Recruiting |
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| MNCCTN Essentia Health Sandstone | Sandstone | Minnesota | 550723 | Recruiting |
| MNCCTN Essentia Health Virginia Clinic | Virginia | Minnesota | 55792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04105270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04105270 live on ClinicalTrials.gov.